{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:40:56Z","timestamp":1793310056048,"version":"4.5.0"},"reference-count":262,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"Abstract<\/jats:title>Context<\/jats:title>Antiresorptive therapy significantly reduces fracture risk in patients with benign bone disease and skeletal-related events (SREs) in patients with bone metastases (BM). Osteonecrosis of the jaw (ONJ) is a rare but severe condition manifested as necrotic bone lesion or lesions of the jaws. ONJ has been linked to the use of potent antiresorptive agents, termed medication-related ONJ (MRONJ).<\/jats:p><\/jats:sec>Objective<\/jats:title>We aimed to identify the differences various aspects of MRONJ among distinct patient categories and provide recommendations on how to mitigate the risk and optimally manage MRONJ in each of them.<\/jats:p><\/jats:sec>Methods<\/jats:title>A working group of the European Calcified Tissue Society (ECTS) and 2 experts performed an updated detailed review of existing literature on MRONJ incidence, characteristics, and treatment applied in bone diseases with variable severity of skeletal insult, ranging from osteoporosis to prevention of cancer treatment\u2013induced bone loss and SREs in cancer patients with BM.<\/jats:p><\/jats:sec>Results<\/jats:title>The risk for MRONJ is much higher in patients with advanced malignancies compared to those with benign bone diseases because of the higher doses and more frequent administration of antiresorptive agents in individuals with compromised general health, along with coadministration of other medications that predispose to MRONJ. The overall risk for MRONJ is considerably lower than the benefits in all categories of patients.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The risk for MRONJ largely depends on the underlying bone disease and the relevant antiresorptive regimen applied. Physicians and dentists should keep in mind that the benefits of antiresorptive therapy far outweigh the risk for MRONJ development.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgab888","type":"journal-article","created":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T23:17:31Z","timestamp":1639869451000},"page":"1441-1460","source":"Crossref","is-referenced-by-count":130,"title":["Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D","family":"Anastasilakis","sequence":"first","affiliation":[{"name":"Department of Endocrinology, 424 General Military Hospital, 564 29 N Efkarpia Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pepe","sequence":"additional","affiliation":[{"name":"Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, \u201cSapienza\u201d University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Departmental Faculty of Medicine and Surgery, Campus Bio-Medico University of Rome, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Departmental Faculty of Medicine and Surgery, Campus Bio-Medico University of Rome, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Magopoulos","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, 424 General Military Hospital, 56429 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Geriatrics, McMaster University, L8N3Z5 Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Carola","family":"Zillikens","sequence":"additional","affiliation":[{"name":"Bone Center, Department of Internal Medicine, Erasmus MC , 2040 Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Body","sequence":"additional","affiliation":[{"name":"Department of Medicine, CHU Brugmann, Universit\u00e9 Libre de Bruxelles, 1050 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,12,18]]},"reference":[{"issue":"6717","key":"2022042011065463400_CIT0001","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature."},{"key":"2022042011065463400_CIT0002","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.amjmed.2008.12.003","article-title":"Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis","volume":"122","author":"Bilezikian","year":"2009","journal-title":"Am J Med."},{"issue":"8","key":"2022042011065463400_CIT0003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"8","key":"2022042011065463400_CIT0004","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer."},{"key":"2022042011065463400_CIT0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbo.2017.09.003","article-title":"The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"9","author":"Zhang","year":"2017","journal-title":"J Bone Oncol."},{"issue":"10","key":"2022042011065463400_CIT0006","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0007","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: a systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis."},{"issue":"8","key":"2022042011065463400_CIT0008","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","article-title":"A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics","volume":"29","author":"Pazianas","year":"2007","journal-title":"Clin Ther."},{"issue":"2","key":"2022042011065463400_CIT0009","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer."},{"issue":"8","key":"2022042011065463400_CIT0010","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J Cancer Res Clin Oncol."},{"issue":"1","key":"2022042011065463400_CIT0011","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal."},{"issue":"1","key":"2022042011065463400_CIT0012","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singapore Dent J."},{"issue":"7","key":"2022042011065463400_CIT0013","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bcp.14681","article-title":"Medication-related osteonecrosis of the jaw: analysing the range of implicated drugs from the Australian database of adverse event notifications","volume":"87","author":"Teoh","year":"2021","journal-title":"Br J Clin Pharmacol."},{"issue":"7","key":"2022042011065463400_CIT0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1601-0825.2012.01911.x","article-title":"Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines","volume":"18","author":"Patel","year":"2012","journal-title":"Oral Dis."},{"issue":"1","key":"2022042011065463400_CIT0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","article-title":"Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed","volume":"53","author":"Fedele","year":"2015","journal-title":"Br J Oral Maxillofac Surg."},{"key":"2022042011065463400_CIT0016","article-title":"Supplementary data for \u201cOsteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS.\u201d","author":"Anastasilakis"},{"key":"2022042011065463400_CIT0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0018","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.bone.2013.08.007","article-title":"Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors","volume":"57","author":"Vermeer","year":"2013","journal-title":"Bone."},{"issue":"1","key":"2022042011065463400_CIT0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1902\/jop.2013.130094","article-title":"Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy","volume":"85","author":"Kuroshima","year":"2014","journal-title":"J Periodontol."},{"issue":"3","key":"2022042011065463400_CIT0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jcms.2017.12.027","article-title":"Effect of different doses and durations of teriparatide therapy on resolution of medication-related osteonecrosis of the jaw: a randomized, controlled preclinical study in rats","volume":"46","author":"Zandi","year":"2018","journal-title":"J Craniomaxillofac Surg."},{"issue":"11","key":"2022042011065463400_CIT0021","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.ijom.2013.05.001","article-title":"The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: an animal study","volume":"42","author":"Dayisoylu","year":"2013","journal-title":"Int J Oral Maxillofac Surg."},{"issue":"25","key":"2022042011065463400_CIT0022","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1005361","article-title":"Teriparatide and osseous regeneration in the oral cavity","volume":"363","author":"Bashutski","year":"2010","journal-title":"N Engl J Med."},{"issue":"6","key":"2022042011065463400_CIT0023","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tripleo.2011.04.020","article-title":"A model for the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw and teriparatide\u2019s potential role in its resolution","volume":"112","author":"Subramanian","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"11","key":"2022042011065463400_CIT0024","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol."},{"issue":"10","key":"2022042011065463400_CIT0025","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2022042011065463400_CIT0026","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","volume":"28","author":"Kang","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2022042011065463400_CIT0027","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.joms.2007.11.035","article-title":"Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy","volume":"66","author":"Sedghizadeh","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"issue":"8","key":"2022042011065463400_CIT0028","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.archoralbio.2014.05.002","article-title":"Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws","volume":"59","author":"Boff","year":"2014","journal-title":"Arch Oral Biol."},{"issue":"6","key":"2022042011065463400_CIT0029","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00774-009-0090-6","article-title":"Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats","volume":"27","author":"Hikita","year":"2009","journal-title":"J Bone Miner Metab."},{"issue":"5","key":"2022042011065463400_CIT0030","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.archoralbio.2010.11.003","article-title":"Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts","volume":"56","author":"Ravosa","year":"2011","journal-title":"Arch Oral Biol."},{"issue":"2","key":"2022042011065463400_CIT0031","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00774-009-0128-9","article-title":"Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice","volume":"28","author":"Kobayashi","year":"2010","journal-title":"J Bone Miner Metab."},{"issue":"2","key":"2022042011065463400_CIT0032","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood."},{"key":"2022042011065463400_CIT0033","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jsbmb.2019.01.009","article-title":"Glucocorticoid-mediated effects on angiogenesis in solid tumors","volume":"188","author":"Martens","year":"2019","journal-title":"J Steroid Biochem Mol Biol."},{"issue":"3","key":"2022042011065463400_CIT0034","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"issue":"14","key":"2022042011065463400_CIT0035","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4161\/cbt.22274","article-title":"Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid","volume":"13","author":"Misso","year":"2012","journal-title":"Cancer Biol Ther."},{"issue":"1","key":"2022042011065463400_CIT0036","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology."},{"issue":"15 Pt 1","key":"2022042011065463400_CIT0037","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2022042011065463400_CIT0038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2008.04.013","article-title":"Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients","volume":"45","author":"Sonis","year":"2009","journal-title":"Oral Oncol."},{"issue":"7","key":"2022042011065463400_CIT0039","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jbmr.37","article-title":"Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice","volume":"25","author":"Kikuiri","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022042011065463400_CIT0040","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.07.145","article-title":"Vascular endothelial growth factor receptors in osteoclast differentiation and function","volume":"335","author":"Aldridge","year":"2005","journal-title":"Biochem Biophys Res Commun."},{"issue":"3","key":"2022042011065463400_CIT0041","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/jnci\/djq516","article-title":"Osteonecrosis of the jaw and the role of macrophages","volume":"103","author":"Pazianas","year":"2011","journal-title":"J Natl Cancer Inst."},{"issue":"24","key":"2022042011065463400_CIT0042","doi-asserted-by":"crossref","first-page":"20002","DOI":"10.18632\/oncotarget.4755","article-title":"Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation","volume":"6","author":"Tseng","year":"2015","journal-title":"Oncotarget."},{"issue":"5","key":"2022042011065463400_CIT0043","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0044","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00784-010-0507-6","article-title":"The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes\u2013in vitro study","volume":"16","author":"Pabst","year":"2012","journal-title":"Clin Oral Investig."},{"issue":"3","key":"2022042011065463400_CIT0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.amjoto.2006.08.004","article-title":"Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals","volume":"28","author":"Magopoulos","year":"2007","journal-title":"Am J Otolaryngol."},{"issue":"3","key":"2022042011065463400_CIT0046","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bone.2007.04.196","article-title":"Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?","volume":"41","author":"Reid","year":"2007","journal-title":"Bone."},{"issue":"2","key":"2022042011065463400_CIT0047","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/nu13020561","article-title":"Medication-related osteonecrosis of the jaw (MRONJ): are antiresorptive drugs the main culprits or only accomplices? The triggering role of vitamin D deficiency","volume":"13","author":"Dalle Carbonare","year":"2021","journal-title":"Nutrients."},{"issue":"12","key":"2022042011065463400_CIT0048","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jcms.2017.09.015","article-title":"Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw","volume":"45","author":"Heim","year":"2017","journal-title":"J Craniomaxillofac Surg."},{"issue":"2","key":"2022042011065463400_CIT0049","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/njcp.njcp_374_19","article-title":"Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: a case control study","volume":"23","author":"Demircan","year":"2020","journal-title":"Niger J Clin Pract."},{"issue":"5","key":"2022042011065463400_CIT0050","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jbmr.3395","article-title":"Evaluation of a multimodal, direct-to-patient educational intervention targeting barriers to osteoporosis care: a randomized clinical trial","volume":"33","author":"Danila","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"8907","key":"2022042011065463400_CIT0051","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(94)92446-5","article-title":"Mineralisation defects after pamidronate for Paget\u2019s disease","volume":"343","author":"Boyce","year":"1994","journal-title":"Lancet."},{"issue":"8","key":"2022042011065463400_CIT0052","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/theoncologist.2012-0141","article-title":"Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?","volume":"17","author":"Bedogni","year":"2012","journal-title":"Oncologist."},{"issue":"2","key":"2022042011065463400_CIT0053","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000342120","article-title":"Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis","volume":"129","author":"Zhong","year":"2013","journal-title":"Acta Haematol."},{"issue":"3","key":"2022042011065463400_CIT0054","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijom.2019.07.016","article-title":"Pharmacogenetics of medication-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"49","author":"Guo","year":"2020","journal-title":"Int J Oral Maxillofac Surg."},{"issue":"7","key":"2022042011065463400_CIT0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/odi.12355","article-title":"Genetic association between VEGF polymorphisms and BRONJ in the Korean population","volume":"21","author":"Choi","year":"2015","journal-title":"Oral Dis."},{"issue":"4","key":"2022042011065463400_CIT0056","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2011.08622.x","article-title":"A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling","volume":"154","author":"Di Martino","year":"2011","journal-title":"Br J Haematol."},{"issue":"2","key":"2022042011065463400_CIT0057","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2217\/bmm.12.14","article-title":"An aromatase polymorphism (g.132810C\u2005>\u2005T) predicts risk of bisphosphonate-related osteonecrosis of the jaw","volume":"6","author":"La Ferla","year":"2012","journal-title":"Biomark Med."},{"key":"2022042011065463400_CIT0058","first-page":"364","article-title":"Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw","volume":"3","author":"Marini","year":"2011","journal-title":"Front Biosci (Elite Ed)."},{"issue":"2","key":"2022042011065463400_CIT0059","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","article-title":"Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3","volume":"17","author":"Nicoletti","year":"2012","journal-title":"Oncologist."},{"issue":"1","key":"2022042011065463400_CIT0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jbmr.3285","article-title":"SIRT1\/HERC4 locus associated with bisphosphonate-induced osteonecrosis of the jaw: an exome-wide association analysis","volume":"33","author":"Yang","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"23","key":"2022042011065463400_CIT0061","first-page":"10184","article-title":"Pharmacogenomics in medication-related osteonecrosis of the jaw: a systematic literature review","volume":"23","author":"Bastida-Lertxundi","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"2022042011065463400_CIT0062","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bone.2019.04.010","article-title":"Pharmacogenomics of osteonecrosis of the jaw","volume":"124","author":"Yang","year":"2019","journal-title":"Bone."},{"issue":"6","key":"2022042011065463400_CIT0063","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00520-020-05855-6","article-title":"Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review","volume":"29","author":"Querrer","year":"2021","journal-title":"Support Care Cancer."},{"issue":"1","key":"2022042011065463400_CIT0064","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2022042011065463400_CIT0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1834-7819.2003.tb00011.x","article-title":"Oral ulceration with bone sequestration","volume":"48","author":"Farah","year":"2003","journal-title":"Aust Dent J."},{"issue":"8","key":"2022042011065463400_CIT0066","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1902\/jop.1997.68.8.758","article-title":"Spontaneous bony exposure: a report of 4 cases of idiopathic exposure and sequestration of alveolar bone","volume":"68","author":"Sonnier","year":"1997","journal-title":"J Periodontol."},{"issue":"6","key":"2022042011065463400_CIT0067","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0030-4220(93)90433-5","article-title":"Lingual mandibular sequestration and ulceration","volume":"75","author":"Peters","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol."},{"issue":"3","key":"2022042011065463400_CIT0068","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.bdj.4801315","article-title":"Oral ulceration: a new and unusual complication","volume":"192","author":"Scully","year":"2002","journal-title":"Br Dent J."},{"issue":"18","key":"2022042011065463400_CIT0069","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"3","key":"2022042011065463400_CIT0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"key":"2022042011065463400_CIT0071","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"22","key":"2022042011065463400_CIT0072","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med."},{"issue":"3","key":"2022042011065463400_CIT0073","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0074","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom."},{"issue":"4","key":"2022042011065463400_CIT0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00774-010-0162-7","article-title":"Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons","volume":"28","author":"Yoneda","year":"2010","journal-title":"J Bone Miner Metab."},{"issue":"11","key":"2022042011065463400_CIT0076","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.joms.2011.03.051","article-title":"Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"69","author":"Urade","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0077","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Japanese Allied Committee on Osteonecrosis of the Jaw;","year":"2017","journal-title":"J Bone Miner Metab."},{"issue":"25","key":"2022042011065463400_CIT0078","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022042011065463400_CIT0079","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg."},{"issue":"9757","key":"2022042011065463400_CIT0080","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet."},{"issue":"11","key":"2022042011065463400_CIT0081","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc."},{"issue":"10","key":"2022042011065463400_CIT0082","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2014a review","volume":"48","author":"K\u00fchl","year":"2012","journal-title":"Oral Oncol."},{"issue":"1","key":"2022042011065463400_CIT0083","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2022042011065463400_CIT0084","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA."},{"issue":"3","key":"2022042011065463400_CIT0085","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11845-019-02120-6","article-title":"Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit","volume":"189","author":"Bal","year":"2020","journal-title":"Ir J Med Sci."},{"issue":"2","key":"2022042011065463400_CIT0086","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"2022042011065463400_CIT0087","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00520-020-05355-7","article-title":"Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency","volume":"28","author":"Yang","year":"2020","journal-title":"Support Care Cancer."},{"issue":"8","key":"2022042011065463400_CIT0088","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1007\/s00520-021-06018-x","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue","year":"2021","journal-title":"Support Care Cancer."},{"issue":"2","key":"2022042011065463400_CIT0089","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"issue":"3","key":"2022042011065463400_CIT0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jds.2017.12.003","article-title":"Clinical analysis of medication related osteonecrosis of the jaws: a growing severe complication in China","volume":"13","author":"Wang","year":"2018","journal-title":"J Dent Sci."},{"issue":"7","key":"2022042011065463400_CIT0091","doi-asserted-by":"crossref","first-page":"e0201343","DOI":"10.1371\/journal.pone.0201343","article-title":"Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor?","volume":"13","author":"Soutome","year":"2018","journal-title":"PLoS One."},{"issue":"1","key":"2022042011065463400_CIT0092","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-018-4746-8","article-title":"Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study","volume":"30","author":"Hasegawa","year":"2019","journal-title":"Osteoporos Int."},{"issue":"5","key":"2022042011065463400_CIT0093","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00520-020-05748-8","article-title":"Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307)","volume":"29","author":"Kizub","year":"2021","journal-title":"Support Care Cancer."},{"issue":"5","key":"2022042011065463400_CIT0094","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol."},{"issue":"3","key":"2022042011065463400_CIT0095","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0714.2011.01095.x","article-title":"Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome","volume":"41","author":"Fortuna","year":"2012","journal-title":"J Oral Pathol Med."},{"issue":"34","key":"2022042011065463400_CIT0096","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022042011065463400_CIT0097","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/annonc\/mdm370","article-title":"A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients","volume":"18","author":"Jadu","year":"2007","journal-title":"Ann Oncol."},{"issue":"32","key":"2022042011065463400_CIT0098","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol."},{"key":"2022042011065463400_CIT0099","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","article-title":"Osteonecrosis of the jaw and the role of bisphosphonates: a critical review","volume":"122","author":"Silverman","year":"2009","journal-title":"Am J Med."},{"issue":"1","key":"2022042011065463400_CIT0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"2022042011065463400_CIT0101","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol."},{"issue":"4","key":"2022042011065463400_CIT0102","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.joms.2011.02.093","article-title":"Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study","volume":"70","author":"Vestergaard","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"issue":"3","key":"2022042011065463400_CIT0103","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int."},{"issue":"12","key":"2022042011065463400_CIT0104","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.joms.2016.06.003","article-title":"Patients receiving parenteral bisphosphonates for malignant disease and having developed an atypical femoral fracture are at risk of concomitant osteonecrosis of the jaw: an evidence-based review","volume":"74","author":"Graves","year":"2016","journal-title":"J Oral Maxillofac Surg."},{"issue":"10","key":"2022042011065463400_CIT0105","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00198-017-4132-y","article-title":"Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users","volume":"28","author":"Eiken","year":"2017","journal-title":"Osteoporos Int."},{"issue":"2","key":"2022042011065463400_CIT0106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.11622\/smedj.2018014","article-title":"Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management","volume":"59","author":"Chan","year":"2018","journal-title":"Singapore Med J."},{"issue":"5","key":"2022042011065463400_CIT0107","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5125\/jkaoms.2018.44.5.225","article-title":"Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw","volume":"44","author":"Kang","year":"2018","journal-title":"J Korean Assoc Oral Maxillofac Surg."},{"issue":"10","key":"2022042011065463400_CIT0108","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.joms.2018.04.009","article-title":"National survey on bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"76","author":"Shibahara","year":"2018","journal-title":"J Oral Maxillofac Surg."},{"issue":"2","key":"2022042011065463400_CIT0109","doi-asserted-by":"crossref","first-page":"e024655","DOI":"10.1136\/bmjopen-2018-024655","article-title":"Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sj\u00f6gren\u2019s syndrome: nationwide population-based cohort study","volume":"9","author":"Liao","year":"2019","journal-title":"BMJ Open."},{"issue":"30","key":"2022042011065463400_CIT0110","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.2217\/fon-2019-0352","article-title":"Risk factors for developing osteonecrosis of jaw in advanced cancer patients underwent zoledronic acid treatment","volume":"15","author":"Qi","year":"2019","journal-title":"Future Oncol."},{"issue":"4","key":"2022042011065463400_CIT0111","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0112","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am J Clin Oncol."},{"issue":"6","key":"2022042011065463400_CIT0113","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijom.2011.02.002","article-title":"Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw","volume":"40","author":"Katz","year":"2011","journal-title":"Int J Oral Maxillofac Surg."},{"issue":"6","key":"2022042011065463400_CIT0114","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/jbmr.2179","article-title":"A large case-control study reveals a positive association between bisphosphonate use and delayed dental healing and osteonecrosis of the jaw","volume":"29","author":"Borromeo","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022042011065463400_CIT0115","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1210\/jc.2006-2036","article-title":"Possible association between diabetes and bisphosphonate-related jaw osteonecrosis","volume":"92","author":"Khamaisi","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022042011065463400_CIT0116","first-page":"e26","article-title":"Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: a systematic review","volume":"24","author":"Lorenzo-Pouso","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal."},{"issue":"4","key":"2022042011065463400_CIT0117","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.4317\/medoral.24318","article-title":"A multicenter observational study on medication-related osteonecrosis of the jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy","volume":"26","author":"Fusco","year":"2021","journal-title":"Med Oral Patol Oral Cir Bucal."},{"issue":"3","key":"2022042011065463400_CIT0118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","article-title":"Osteonecrosis of the jaws induced by anti-RANK ligand therapy","volume":"48","author":"Taylor","year":"2010","journal-title":"Br J Oral Maxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0b013e31824be20e","article-title":"Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis","volume":"36","author":"Sun","year":"2013","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"2022042011065463400_CIT0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"2022042011065463400_CIT0121","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol."},{"issue":"3","key":"2022042011065463400_CIT0122","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin Oral Implants Res."},{"issue":"5","key":"2022042011065463400_CIT0123","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00228-017-2210-x","article-title":"Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review","volume":"73","author":"de Boissieu","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"issue":"3","key":"2022042011065463400_CIT0124","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022042011065463400_CIT0125","doi-asserted-by":"crossref","first-page":"e0191455","DOI":"10.1371\/journal.pone.0191455","article-title":"Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis","volume":"13","author":"Hayes","year":"2018","journal-title":"PLoS One."},{"issue":"7","key":"2022042011065463400_CIT0126","doi-asserted-by":"crossref","first-page":"364","DOI":"10.11622\/smedj.2019028","article-title":"Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review","volume":"60","author":"Chandran","year":"2019","journal-title":"Singapore Med J."},{"issue":"6","key":"2022042011065463400_CIT0127","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022042011065463400_CIT0128","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11096-020-01105-1","article-title":"Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis","volume":"43","author":"Chen","year":"2020","journal-title":"Int J Clin Pharm."},{"key":"2022042011065463400_CIT0129","first-page":"CD013020","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"7","key":"2022042011065463400_CIT0130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2022042011065463400_CIT0131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/jbmr.2693","article-title":"Osteonecrosis of the jaw in the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS)","volume":"31","author":"Zhang","year":"2016","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2022042011065463400_CIT0132","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9810","key":"2022042011065463400_CIT0133","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet."},{"issue":"1","key":"2022042011065463400_CIT0134","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"2022042011065463400_CIT0135","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00520-020-05882-3","article-title":"Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis","volume":"29","author":"Srivastava","year":"2021","journal-title":"Support Care Cancer."},{"issue":"2","key":"2022042011065463400_CIT0136","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jbmr.3886","article-title":"Increased fracture risk in women treated with aromatase inhibitors versus tamoxifen: beneficial effect of bisphosphonates","volume":"35","author":"Pineda-Moncus\u00ed","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"10001","key":"2022042011065463400_CIT0137","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"2022042011065463400_CIT0138","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1210\/jc.2013-4119","article-title":"The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene","volume":"99","author":"Chiu","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022042011065463400_CIT0139","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/SCS.0000000000004278","article-title":"Mandibular osteonecrosis associated with raloxifene","volume":"29","author":"Pontes","year":"2018","journal-title":"J Craniofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0140","first-page":"423","article-title":"Osteonecrosis of the jaw in a patient on raloxifene: a case report","volume":"46","author":"Baur","year":"2015","journal-title":"Quintessence Int."},{"issue":"16","key":"2022042011065463400_CIT0141","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2022042011065463400_CIT0142","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs. zoledronic acid: a systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal."},{"issue":"12","key":"2022042011065463400_CIT0143","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol."},{"key":"2022042011065463400_CIT0144","doi-asserted-by":"crossref","DOI":"10.1002\/JBMR.4472\/v2\/response1","article-title":"Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis","author":"Everts-Graber","year":"2021","journal-title":"J Bone Miner Res."},{"issue":"16","key":"2022042011065463400_CIT0145","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer."},{"issue":"2","key":"2022042011065463400_CIT0146","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/17843286.2017.1348001","article-title":"Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab","volume":"73","author":"Loyson","year":"2018","journal-title":"Acta Clin Belg."},{"issue":"6","key":"2022042011065463400_CIT0147","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.oooo.2018.02.010","article-title":"Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw","volume":"125","author":"Higuchi","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"6","key":"2022042011065463400_CIT0148","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00280-021-04262-w","article-title":"Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases","volume":"87","author":"Ikesue","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"issue":"9","key":"2022042011065463400_CIT0149","doi-asserted-by":"crossref","first-page":"981","DOI":"10.14219\/jada.archive.2012.0323","article-title":"Denosumab-related osteonecrosis of the jaw","volume":"143","author":"Diz","year":"2012","journal-title":"J Am Dent Assoc."},{"issue":"2","key":"2022042011065463400_CIT0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcms.2017.11.008","article-title":"The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review","volume":"46","author":"Poubel","year":"2018","journal-title":"J Craniomaxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0151","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1592\/phco.28.5.667","article-title":"Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates","volume":"28","author":"King","year":"2008","journal-title":"Pharmacotherapy."},{"issue":"7","key":"2022042011065463400_CIT0152","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1007\/s00784-018-2349-6","article-title":"Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro","volume":"22","author":"Jung","year":"2018","journal-title":"Clin Oral Investig."},{"issue":"7","key":"2022042011065463400_CIT0153","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica."},{"issue":"7","key":"2022042011065463400_CIT0154","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djz215","article-title":"Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307","volume":"112","author":"Gralow","year":"2020","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"2022042011065463400_CIT0155","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis","volume":"116","author":"Mauri","year":"2009","journal-title":"Breast Cancer Res Treat."},{"issue":"6","key":"2022042011065463400_CIT0156","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/antiox9060503","article-title":"Structure-dependent effects of bisphosphonates on inflammatory responses in cultured neonatal mouse calvaria","volume":"9","author":"Suzuki","year":"2020","journal-title":"Antioxidants (Basel)."},{"issue":"1","key":"2022042011065463400_CIT0157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-824X-5-1","article-title":"Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect","volume":"5","author":"Sharma","year":"2013","journal-title":"Vasc Cell."},{"issue":"3","key":"2022042011065463400_CIT0158","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.joms.2008.09.028","article-title":"The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw","volume":"67","author":"Otto","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"2","key":"2022042011065463400_CIT0159","first-page":"97","article-title":"Painful trigeminal neuropathy induced by oral bisphosphonate-related osteonecrosis of the jaw: a new etiology for the numb-chin syndrome","volume":"43","author":"Zadik","year":"2012","journal-title":"Quintessence Int."},{"issue":"7","key":"2022042011065463400_CIT0160","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.joms.2009.03.048","article-title":"Higher bone matrix density exists in only a subset of patients with bisphosphonate-related osteonecrosis of the jaw","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"6","key":"2022042011065463400_CIT0161","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3174\/ajnr.A0518","article-title":"Imaging findings of bisphosphonate-associated osteonecrosis of the jaws","volume":"28","author":"Phal","year":"2007","journal-title":"AJNR Am J Neuroradiol."},{"issue":"3","key":"2022042011065463400_CIT0162","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijom.2010.11.006","article-title":"Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris","volume":"40","author":"Maurer","year":"2011","journal-title":"Int J Oral Maxillofac Surg."},{"key":"2022042011065463400_CIT0163","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13005-015-0099-0","article-title":"Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla","volume":"12","author":"Voss","year":"2016","journal-title":"Head Face Med."},{"issue":"6","key":"2022042011065463400_CIT0164","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.bjoms.2020.03.010","article-title":"Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis","volume":"58","author":"Murphy","year":"2020","journal-title":"Br J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist."},{"issue":"3","key":"2022042011065463400_CIT0166","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10006-020-00927-7","article-title":"Patients\u2019 quality of life improves after surgical intervention of stage III medication-related osteonecrosis of the jaw","volume":"25","author":"Moll","year":"2021","journal-title":"Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0167","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40264-017-0582-6","article-title":"Treatment of medication-related osteonecrosis of the jaw and its impact on a patient\u2019s quality of life: a single-center, 10-year experience from Southern Italy","volume":"41","author":"Oteri","year":"2018","journal-title":"Drug Saf."},{"issue":"1","key":"2022042011065463400_CIT0168","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41368-020-00093-2","article-title":"Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw","volume":"12","author":"He","year":"2020","journal-title":"Int J Oral Sci."},{"issue":"2","key":"2022042011065463400_CIT0169","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00784-017-2325-6","article-title":"Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol","volume":"22","author":"Ramaglia","year":"2018","journal-title":"Clin Oral Investig."},{"issue":"12","key":"2022042011065463400_CIT0170","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00256-014-1951-1","article-title":"Cone beam computed tomography for diagnosis of bisphosphonate-related osteonecrosis of the jaw: evaluation of quantitative and qualitative image parameters","volume":"43","author":"Guggenberger","year":"2014","journal-title":"Skeletal Radiol."},{"issue":"3","key":"2022042011065463400_CIT0171","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/RLI.0000000000000617","article-title":"Medication-related osteonecrosis of the jaw-comparison of bone imaging using ultrashort echo-time magnetic resonance imaging and cone-beam computed tomography","volume":"55","author":"Huber","year":"2020","journal-title":"Invest Radiol."},{"issue":"7","key":"2022042011065463400_CIT0172","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.joms.2009.03.005","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator","volume":"67","author":"O\u2019Ryan","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0173","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00774-021-01223-4","article-title":"Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis","volume":"39","author":"Aoki","year":"2021","journal-title":"J Bone Miner Metab."},{"issue":"1","key":"2022042011065463400_CIT0174","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol."},{"issue":"11","key":"2022042011065463400_CIT0175","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022042011065463400_CIT0176","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol."},{"issue":"4","key":"2022042011065463400_CIT0177","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/030089161109700411","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies","volume":"97","author":"Bantis","year":"2011","journal-title":"Tumori."},{"issue":"28","key":"2022042011065463400_CIT0178","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022042011065463400_CIT0179","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0180","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.joms.2009.07.068","article-title":"Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series","volume":"68","author":"Lodi","year":"2010","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0181","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The Saxon Bisphosphonate Register\u2014therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2012","journal-title":"Oral Oncol."},{"issue":"6","key":"2022042011065463400_CIT0182","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.joms.2010.10.055","article-title":"Preventive protocol for tooth extractions in patients treated with zoledronate: a case series","volume":"69","author":"Ferlito","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0183","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","article-title":"Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol."},{"issue":"21","key":"2022042011065463400_CIT0184","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.2217\/fon-2020-1240","article-title":"Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy","volume":"17","author":"Laimer","year":"2021","journal-title":"Future Oncol."},{"issue":"6","key":"2022042011065463400_CIT0185","first-page":"469","article-title":"Treatment of the oral complications of leukemia","volume":"35","author":"Segelman","year":"1977","journal-title":"J Oral Surg."},{"issue":"4","key":"2022042011065463400_CIT0186","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0029-6465(22)02073-4","article-title":"Providing optimal oral health","volume":"12","author":"Maurer","year":"1977","journal-title":"Nurs Clin North Am."},{"issue":"12","key":"2022042011065463400_CIT0187","first-page":"2146","article-title":"Oral care of the patient having head and neck irradiation","volume":"75","author":"Trowbridge","year":"1975","journal-title":"Am J Nurs."},{"issue":"8","key":"2022042011065463400_CIT0188","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00520-010-0837-6","article-title":"A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact","volume":"18","author":"Jensen","year":"2010","journal-title":"Support Care Cancer."},{"issue":"11","key":"2022042011065463400_CIT0189","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1007\/s00520-013-1942-0","article-title":"Systematic review of basic oral care for the management of oral mucositis in cancer patients","volume":"21","author":"McGuire","year":"2013","journal-title":"Support Care Cancer."},{"issue":"3","key":"2022042011065463400_CIT0190","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12663-014-0707-8","article-title":"Bisphosphonate-related osteonecrosis of the jaws and its array of manifestations","volume":"14","author":"Rabelo","year":"2015","journal-title":"J Maxillofac Oral Surg."},{"issue":"3","key":"2022042011065463400_CIT0191","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.otohns.2006.11.008","article-title":"Bisphosphonates and jaw osteonecrosis: the UAMS experience","volume":"136","author":"Clarke","year":"2007","journal-title":"Otolaryngol Head Neck Surg."},{"issue":"5","key":"2022042011065463400_CIT0192","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1524-4741.2011.01119.x","article-title":"Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects","volume":"17","author":"Quispe","year":"2011","journal-title":"Breast J."},{"issue":"6","key":"2022042011065463400_CIT0193","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00520-017-4003-2","article-title":"A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer","volume":"26","author":"Schiodt","year":"2018","journal-title":"Support Care Cancer."},{"issue":"8","key":"2022042011065463400_CIT0194","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist."},{"issue":"6","key":"2022042011065463400_CIT0195","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2022042011065463400_CIT0196","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bone.2009.07.011","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?","volume":"45","author":"Lesclous","year":"2009","journal-title":"Bone."},{"issue":"9","key":"2022042011065463400_CIT0197","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.oraloncology.2007.11.012","article-title":"Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies","volume":"44","author":"Boonyapakorn","year":"2008","journal-title":"Oral Oncol."},{"issue":"12","key":"2022042011065463400_CIT0198","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0199","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol."},{"issue":"11","key":"2022042011065463400_CIT0200","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc."},{"issue":"3","key":"2022042011065463400_CIT0201","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1747-4477.2009.00213.x","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw\u20142009 update","volume":"35","author":"Ruggiero","year":"2009","journal-title":"Aust Endod J."},{"issue":"7","key":"2022042011065463400_CIT0202","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol."},{"issue":"3","key":"2022042011065463400_CIT0203","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3899\/jrheum.080759","article-title":"Bisphosphonate associated osteonecrosis of the jaw","volume":"36","author":"Khan","year":"2009","journal-title":"J Rheumatol."},{"issue":"6","key":"2022042011065463400_CIT0204","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.tripleo.2011.07.004","article-title":"A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws","volume":"112","author":"Moretti","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"5","key":"2022042011065463400_CIT0205","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/02841860601185917","article-title":"Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis","volume":"46","author":"Ortega","year":"2007","journal-title":"Acta Oncol."},{"issue":"1","key":"2022042011065463400_CIT0206","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1601-0825.2011.01848.x","article-title":"Antibiotic effects on bacterial profile in osteonecrosis of the jaw","volume":"18","author":"Ji","year":"2012","journal-title":"Oral Dis."},{"key":"2022042011065463400_CIT0207","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.bonr.2021.101072","article-title":"The progress of medication-related osteonecrosis of the jaw with conservative initial treatment: a 12-year retrospective study of 129 patients","volume":"14","author":"Kaibuchi","year":"2021","journal-title":"Bone Rep."},{"issue":"9","key":"2022042011065463400_CIT0208","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hed.21380","article-title":"Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy","volume":"33","author":"Lee","year":"2011","journal-title":"Head Neck."},{"issue":"1","key":"2022042011065463400_CIT0209","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00223-014-9858-3","article-title":"Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient","volume":"95","author":"Neuprez","year":"2014","journal-title":"Calcif Tissue Int."},{"issue":"25","key":"2022042011065463400_CIT0210","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMc1002684","article-title":"Teriparatide therapy for alendronate-associated osteonecrosis of the jaw","volume":"363","author":"Cheung","year":"2010","journal-title":"N Engl J Med."},{"issue":"8","key":"2022042011065463400_CIT0211","first-page":"547","article-title":"Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis","volume":"32","author":"Iwamoto","year":"2012","journal-title":"Clin Drug Investig."},{"issue":"2","key":"2022042011065463400_CIT0212","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1754-4505.2009.00128.x","article-title":"Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report","volume":"30","author":"Narongroeknawin","year":"2010","journal-title":"Spec Care Dentist."},{"issue":"8","key":"2022042011065463400_CIT0213","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3899\/jrheum.081176","article-title":"Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy","volume":"36","author":"Lau","year":"2009","journal-title":"J Rheumatol."},{"issue":"3","key":"2022042011065463400_CIT0214","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.joms.2006.10.076","article-title":"Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]","volume":"65","author":"Harper","year":"2007","journal-title":"J Oral Maxillofac Surg."},{"issue":"12","key":"2022042011065463400_CIT0215","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.ijom.2015.07.018","article-title":"Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings","volume":"44","author":"Kakehashi","year":"2015","journal-title":"Int J Oral Maxillofac Surg."},{"issue":"26","key":"2022042011065463400_CIT0216","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022042011065463400_CIT0217","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1563\/aaid-joi-D-19-00040","article-title":"Treatment of medication-related osteonecrosis of the jaw around the dental implant with a once-weekly teriparatide: a case report and literature review","volume":"45","author":"Kim","year":"2019","journal-title":"J Oral Implantol."},{"issue":"2","key":"2022042011065463400_CIT0218","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jbmr.4188","article-title":"Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study","volume":"36","author":"Gilsenan","year":"2021","journal-title":"J Bone Miner Res."},{"key":"2022042011065463400_CIT0219","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1746-160X-7-16","article-title":"Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw","volume":"7","author":"Cella","year":"2011","journal-title":"Head Face Med."},{"issue":"3","key":"2022042011065463400_CIT0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0714.2011.01091.x","article-title":"Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients","volume":"41","author":"Vescovi","year":"2012","journal-title":"J Oral Pathol Med."},{"issue":"6","key":"2022042011065463400_CIT0221","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers Med Sci."},{"issue":"11","key":"2022042011065463400_CIT0222","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.3390\/jcm9113505","article-title":"Management of medication-related osteonecrosis of the jaw (MRONJ) using leukocyte- and platelet-rich fibrin (L-PRF) and photobiomodulation: a retrospective study","volume":"9","author":"Tenore","year":"2020","journal-title":"J Clin Med."},{"issue":"1","key":"2022042011065463400_CIT0223","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.joms.2017.06.004","article-title":"Use of leukocyte- and platelet-rich fibrin in the treatment of medication-related osteonecrosis of the jaws","volume":"76","author":"Maluf","year":"2018","journal-title":"J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0224","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.oraloncology.2011.08.010","article-title":"Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study","volume":"48","author":"Martins","year":"2012","journal-title":"Oral Oncol."},{"issue":"26","key":"2022042011065463400_CIT0225","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1200\/JCO.20.01633","article-title":"Are we ready to use teriparatide to treat medication-related osteonecrosis of the jaw in clinical practice?","volume":"38","author":"Ripamonti","year":"2020","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022042011065463400_CIT0226","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"1","key":"2022042011065463400_CIT0227","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.joms.2010.07.014","article-title":"Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study","volume":"69","author":"Pautke","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0228","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oooo.2020.10.018","article-title":"Autofluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw (MRONJ): a retrospective single-center study","volume":"131","author":"Otto","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"2","key":"2022042011065463400_CIT0229","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.joms.2010.06.200","article-title":"Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw","volume":"69","author":"Hoefert","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0230","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.oraloncology.2011.02.024","article-title":"Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis","volume":"47","author":"Bedogni","year":"2011","journal-title":"Oral Oncol."},{"issue":"7","key":"2022042011065463400_CIT0231","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0232","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","article-title":"Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws","volume":"137","author":"M\u00fccke","year":"2011","journal-title":"J Cancer Res Clin Oncol."},{"issue":"4","key":"2022042011065463400_CIT0233","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00520-009-0688-1","article-title":"Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up","volume":"18","author":"Stockmann","year":"2010","journal-title":"Support Care Cancer."},{"issue":"11","key":"2022042011065463400_CIT0234","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.joms.2012.05.019","article-title":"Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 cases","volume":"70","author":"Graziani","year":"2012","journal-title":"J Oral Maxillofac Surg."},{"key":"2022042011065463400_CIT0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"5","key":"2022042011065463400_CIT0236","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.joms.2008.12.057","article-title":"Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases","volume":"67","author":"Stanton","year":"2009","journal-title":"J Oral Maxillofac Surg."},{"issue":"6","key":"2022042011065463400_CIT0237","first-page":"2313","article-title":"Surgical management of bisphosphonate-related osteonecrosis of the jaw in oncologic patients: a challenging problem","volume":"31","author":"Eckardt","year":"2011","journal-title":"Anticancer Res."},{"issue":"8","key":"2022042011065463400_CIT0238","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.adaj.2017.04.002","article-title":"Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"148","author":"El-Rabbany","year":"2017","journal-title":"J Am Dent Assoc."},{"issue":"4","key":"2022042011065463400_CIT0239","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin Breast Cancer."},{"issue":"5","key":"2022042011065463400_CIT0240","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bjoms.2011.08.004","article-title":"Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases","volume":"50","author":"Ferlito","year":"2012","journal-title":"Br J Oral Maxillofac Surg."},{"issue":"1","key":"2022042011065463400_CIT0241","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.tripleo.2010.02.020","article-title":"Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study","volume":"110","author":"Scoletta","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"issue":"2","key":"2022042011065463400_CIT0242","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/hed.21708","article-title":"Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws","volume":"34","author":"Wutzl","year":"2012","journal-title":"Head Neck."},{"issue":"12","key":"2022042011065463400_CIT0243","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1002\/hed.25944","article-title":"Adjuvant therapies in the management of medication-related osteonecrosis of the jaws: systematic review","volume":"41","author":"de Souza Tolentino","year":"2019","journal-title":"Head Neck."},{"issue":"4","key":"2022042011065463400_CIT0244","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.5395\/rde.2019.44.e42","article-title":"Dental care for patients taking antiresorptive drugs: a literature review","volume":"44","author":"Song","year":"2019","journal-title":"Restor Dent Endod."},{"issue":"2","key":"2022042011065463400_CIT0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00520-016-3492-8","article-title":"Response to letter to the editors\u2014safety of long-term denosumab therapy","volume":"25","author":"Stopeck","year":"2017","journal-title":"Support Care Cancer."},{"issue":"1","key":"2022042011065463400_CIT0246","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"16","key":"2022042011065463400_CIT0247","doi-asserted-by":"crossref","first-page":"59-98","DOI":"10.3390\/ijerph17165998","article-title":"Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int J Environ Res Public Health."},{"issue":"8","key":"2022042011065463400_CIT0248","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1601-0825.2009.01581.x","article-title":"Dental management of patients at risk of osteochemonecrosis of the jaws: a critical review","volume":"15","author":"Fedele","year":"2009","journal-title":"Oral Dis."},{"key":"2022042011065463400_CIT0249","doi-asserted-by":"crossref","first-page":"115412","DOI":"10.1016\/j.bone.2020.115412","article-title":"Alendronate or zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis","volume":"137","author":"Lesclous","year":"2020","journal-title":"Bone."},{"issue":"7","key":"2022042011065463400_CIT0250","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0022034520986804","article-title":"Antiresorptive-type and discontinuation-timing affect ONJ burden","volume":"100","author":"Hadaya","year":"2021","journal-title":"J Dent Res."},{"issue":"2","key":"2022042011065463400_CIT0251","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ajoms.2020.09.002","article-title":"Adverse events caused by the discontinuation of anti-resorptive agents during treatment for anti-resorptive agent-related osteonecrosis of the jaw: a single-center cohort study","volume":"33","author":"Yoshida","year":"2021","journal-title":"J Oral Maxillofac Surg Med Pathol."},{"issue":"8","key":"2022042011065463400_CIT0252","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00198-017-4063-7","article-title":"A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?","volume":"28","author":"Hasegawa","year":"2017","journal-title":"Osteoporos Int."},{"issue":"6","key":"2022042011065463400_CIT0253","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.joms.2010.06.197","article-title":"Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw?","volume":"69","author":"Gallego","year":"2011","journal-title":"J Oral Maxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0254","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expert Opin Pharmacother."},{"issue":"11","key":"2022042011065463400_CIT0255","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-021-05995-3","article-title":"Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study","volume":"32","author":"Hasegawa","year":"2021","journal-title":"Osteoporos Int."},{"issue":"3","key":"2022042011065463400_CIT0256","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00198-017-4334-3","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis","volume":"29","author":"Niimi","year":"2018","journal-title":"Osteoporos Int."},{"key":"2022042011065463400_CIT0257","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bone.2017.12.015","article-title":"Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ!","volume":"108","author":"Leaney","year":"2018","journal-title":"Bone."},{"key":"2022042011065463400_CIT0258","author":"US Food and Drug Administration"},{"issue":"10","key":"2022042011065463400_CIT0259","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jcms.2017.07.014","article-title":"Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws\u2014a retrospective cohort study","volume":"45","author":"Martins","year":"2017","journal-title":"J Craniomaxillofac Surg."},{"issue":"4","key":"2022042011065463400_CIT0260","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.oooo.2015.10.033","article-title":"Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III","volume":"121","author":"Bodem","year":"2016","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"issue":"2","key":"2022042011065463400_CIT0261","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.tripleo.2011.02.037","article-title":"Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center","volume":"112","author":"Nicolatou-Galitis","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"2022042011065463400_CIT0262","doi-asserted-by":"crossref","first-page":"115-150","DOI":"10.1016\/j.bone.2019.115150","article-title":"Fracture incidence after denosumab discontinuation: real-world data from a large healthcare provider","volume":"130","author":"Tripto-Shkolnik","year":"2020","journal-title":"Bone."}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab888\/42091375\/dgab888.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/1441\/43400998\/dgab888.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/1441\/43400998\/dgab888.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:14:14Z","timestamp":1699967654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/5\/1441\/6469944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,18]]},"references-count":262,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,18]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab888","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,12,18]]}}}